Olanzapine Plasma Concentration, Average Daily Dose, And

Total Page:16

File Type:pdf, Size:1020Kb

Olanzapine Plasma Concentration, Average Daily Dose, And N. Bergemann1 Olanzapine Plasma Concentration, Average Daily A. Frick1 Dose, and Interaction with Co-Medication in P. Parzer2 J. Kopitz3 Schizophrenic Patients Original Paper Background: Olanzapine, a thienobenzodiazepine, is one of the fect the dose-corrected plasma levels. However, women received relatively new atypical antipsychotic drugs. The lowest threshold a significantly lower daily dose of olanzapine under routine clin- of effective olanzapine plasma levels in inpatient treatment is as- ical study conditions. No differences could be detected among sumed to be 9 ng/ml [28]. Very little is known about the plasma the dose-corrected plasma concentration of those patients who concentration in patients at various oral doses of olanzapine or were taken off olanzapine because they did not respond about the clinically relevant interactions with co-medications. 5n=14) or because of side effects 5n=5) and those who were Methods: In 71 schizophrenic patients 5age 32.6 12.1, range discharged while still on olanzapine. Under the co-medication 18±63 years; 31 women, 40 men), plasma olanzapine levels with fluvoxamine, significantly higher dose-corrected olanza- were assessed in 377 tests by high-performance liquid chroma- pine plasma concentrations were found than with olanzapine tography 5HPLC) with electrochemical detection. Fifty-six of monotherapy, whereas significantly lower dose-corrected olan- these plasma levels were assessed while patients were receiving zapine plasma concentrations were detected under lithium and olanzapine as monotherapy; otherwise, the plasma levels were trimipramine co-medication. Under co-medication with amitrip- assessed with the patients receiving various co-medications. tyline, benperidol, carbamazepine, flupentixol, and lorazepam, Results: The mean daily oral dose of olanzapine was 17.5 mg the dose-corrected olanzapine plasma concentrations were no 5SD = 7.0, range 5±40 mg), and the mean olanzapine plasma different than the plasma levels under olanzapine monotherapy. concentration was 54.2 ng/ml 5SD 37.8 ng/ml, range 1.2±208 ng/ Conclusions: The relevance of therapeutic drug monitoring is 63 ml). The plasma concentration of olanzapine increased linearly emphasized with respect to the data presented and to the litera- with the daily oral dose 5r=0.64, p < 0.001). A multiple variance ture. Future studies should examine, in particular, the effects of a analysis considering age and sex as covariables showed a signifi- wider range of co-medications in a larger patient sample. cant difference in the dose-corrected plasma levels of olanzapine among 40 smokers and 31 non-smokers; age and sex did not af- Introduction in comparison with haloperidol [3,4,33]. Furthermore, like the other atypical neuroleptics, olanzapine has the advantage over Olanzapine is a relatively new atypical neuroleptic from the the classic neuroleptics not only of being effective in treating group of thienobenzodiazepines and is considered to be highly the positive symptoms such as delusions and hallucinations but effective in treating schizophrenia. Its antipsychotic efficacy has also of having a therapeutic effect on the negative symptoms, been well substantiated in placebo-controlled studies as well as such as marked apathy and language poverty, and on affective Affiliation 1 Department of Psychiatry, University of Heidelberg 2 Department of Child- and Adolescent Psychiatry, University of Heidelberg 3 Institute of Pathochemistry and General Neurochemistry, University of Heidelberg Correspondence Dr. med. Dipl.-Psych. Niels Bergemann ´ Department of Psychiatry, University of Heidelberg ´ Voss-Str. 4 ´ D-69118 Heidelberg ´ Germany ´ Phone: +4950)6221/56-5411, -4466 ´ Fax: +4950)6221/56-5477 ´ E-Mail: [email protected] Received 12.10.2000 ´ Revised 21.2.2001 ´ Accepted 24.1.2003 Bibliography Pharmacopsychiatry 2004; 37: 63±68 ´ Georg Thieme Verlag Stuttgart ´ New York ´ ISSN 0176-3679 ´ DOI 10.1055/s-2004-815527 and cognitive disturbances [34,35]. In comparison with the con- Methods ventional neuroleptics, significantly fewer extrapyramidal side effects are present. In addition, there are far fewer changes in Study sample the EEG than with clozapine, a lower incidence of orthostatic hy- Altogether, 377 olanzapine plasma levels were determined at potonia, no influence on the QTc interval, and a mostly transient regular intervals in 71 inpatients being treated at the Depart- increase in transaminase and prolactin levels similar to those of ment of Psychiatry at the University of Heidelberg 5age mean clozapine 5cf. [11,24]). However, a higher rate of side effects such SD: 32.6 12.1, range 18±63 years, 31 women, 40 men). The pa- as dryness of the mouth, increase in appetite, and weight gain tients were receiving olanzapine to treat either a schizophrenic were found [2,17,37]. Preliminary findings have shown that psychosis 5ICD 10: F20.0±20.9) or an affective schizophrenic dis- olanzapine is superior to haloperidol in preventing relapse [36]. order 5ICD 10: F25.0±25.9). Of the patients, 31 were smokers and The recommended starting dose is 10 mg/day; further adjust- 40 were non-smokers. For each patient up to 23 tests were car- ment of the daily dose is recommended according to the individ- ried out, and the mean number of plasma levels assessed for ual's clinical features [25]. each patient was 5.3. Original Paper The chemical structure and receptor-binding profile of olanza- As with typical groups of schizophrenic inpatients, the women pine are similar to that of clozapine. Olanzapine has D4-receptor were significantly older than the men 5age mean SD: 36.5 affinity as well as relatively strong anti-alpha1-adrenergic and 14.1 vs. 29.5 9.5; t-test: t=±2.47, p=0.016) and the men antihistaminergic properties, which account for the sedating ef- were smokers significantly more often than the women 555% fect. In vitro data suggest that the anticholinergic effects of olan- smokers in men vs. 29% smokers in women, c2 = 4.78, df = 1, zapine are similar to those of clozapine 5cf. [8]). In vivo, olanza- p=0.029). Furthermore, smokers were significantly younger pine produces fewer adverse anticholinergic side effects than than non-smokers, regardless of the sex 5ANOVA of age with fac- clozapine. tors smoking and sex, effect of factor smoking: F=6.22, df = 1, p=0.015). To date, little is known about the significance of plasma concen- trations of olanzapine for therapy or about the correlation with Fifty-six olanzapine plasma levels were assessed while patients clinical efficacy. By applying the statistical procedure of a recei- were receiving olanzapine as monotherapy; otherwise, the plas- ver-operating characteristic 5ROC) curve analysis, Perry et al. [28] ma levels were assessed with the patients receiving various co- suggested that the therapeutic range is above 9 ng/ml. Under medications 5n=321). Fifty-two patients were discharged with clinical conditions there is a broad inter-individual variability of olanzapine as medication. In 14 patients olanzapine treatment the dose-corrected plasma levels with therapeutic dose regi- was discontinued because of being ineffective and in five pa- mens [18]. This variability may be the result of different factors, tients, because of adverse side effects 5weight gain in three cases among which are the influence of age, sex, and cigarette smoking and somnolence in two cases). 64 and the effect of different co-medications. Blood specimens and laboratory analysis The bioavailability of olanzapine lies between 80% and 100%. Blood specimens were taken between 08:00 and 09:00 a.m., The rate of protein binding is 93%, whereby olanzapine usually i. e., 10±24 h after the last oral dose of olanzapine in steady state binds to albumin and a1-acid glycoprotein. Absorption occurs 5the daily dose had not been changed for at least 7 days). The soon after oral intake, and the maximum plasma concentration plasma olanzapine levels were determined using high-per- is reached after approximately 5 hours. Food intake has no ef- formance liquid chromatography 5HPLC) with electrochemical fect on absorption [16]. More than 80% of olanzapine is meta- detection. The method was adapted from published procedures bolized to numerous products [19], mainly via the enzymes [12,13]. Samples 51 ml plasma) were diluted with an equal vol- CYP1A2 and CYP2D6, but also via CYP3A4 of the cytochrome ume of SPE buffer 5100 mM ascorbic acid/50 mM potassium P450 system and through formation of N-glucuronides. Olanza- phosphate buffer, pH 6.0) and applied to a bonded-silica solid- pine-10-N-glucuronide is the major metabolite; less abundant phase extraction column 5Bond Elut Certify, Varian, Harbor ones are olanzapine-4¢-N-oxide and 4¢-N-desmethylolanzapine City, USA). The column then was washed by the successive ap- [30,31]. In humans, metabolites are excreted into the urine; plication of 5 ml SPE buffer, 1 ml methanol/borate buffer pH 10 however, even severe renal damage does not affect olanzapine 53:7; v/v), 1 ml 1 M acetic acid, and 5 ml methanol. Finally, clearance [10]. olanzapine was eluted with 3 ml ethyl acetate/1 M ammonium hydroxide 597: 3; v/v). The eluate was evaporated in a stream of The aim of the present investigation was to elucidate the factors nitrogen and the remainder was re-dissolved in 0.5 ml mobile that affect olanzapine levels in schizophrenic patients. For this phase and separated by HPLC on a Hypersil C18 column 55 mm purpose, the following questions were addressed: particle size, dimension: 2504.6 mm, Varian) at 458C. The ± What ranges of olanzapine plasma concentrations are found mobile phase constituted of H2O/methanol/acetonitrile/tri- when therapy is guided by clinical impression? ethylamine 54 : 5:1 : 0,02; v/v/v/v; pH adjusted to 7.0 with phos- ± How do the daily dose and the plasma levels of olanzapine phoric acid) and the flow rate was 0.2 ml/min.
Recommended publications
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • Olanzapine-Induced Acute Pancreatitis and New Diabetes Mellitus
    Open Journal of Psychiatry, 2012, 2, 110-112 OJPsych http://dx.doi.org/10.4236/ojpsych.2012.22015 Published Online April 2012 (http://www.SciRP.org/journal/ojpsych/) Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus Erik Monasterio1*, Ruchi Bhalla2, Andrew McKean3 1Department of Psychological Medicine, University of Otago, Christchurch, New Zealand 2Hammersmith and Fulham Mental Health Unit, West London Mental Health NHS Trust, London, UK 3Hillmorton Hospital, Christchurch, New Zealand Email: *[email protected] Received 29 December 2011; revised 31 January 2012; accepted 15 February 2012 ABSTRACT criteria and required application from a psychiatrist for a patient who had been trialled unsuccessfully on risperi- The aim of this case study is to review the literature done or required treatment with olanzapine short acting and report the first published case of olanzapine-in- intra-muscular injection [4]. In June 2011, significantly duced acute pancreatitis in New Zealand. A case re- cheaper generic versions of olanzapine were introduced port of acute pancreatitis with new onset diabetes and the special authority criteria for olanzapine with- mellitus secondary to olanzapine in a 42-year-old male, drawn [5]. We aim to highlight lesser known and poten- in the absence of medical risk factors is reported. tially fatal side effects through our case report. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 2. CASE REPORT 42-year-old male was diagnosed with acute pancreati- tis and new diabetes mellitus induced by olanzapine. Mr. X is a 42 year old man who had come into contact Although rare, pancreatitis is associated with use of with mental health services on many occasions during some atypical antipsychotic medications.
    [Show full text]
  • Olanzapine and Clozapine Increase the Gabaergic Neuroactive Steroid Allopregnanolone in Rodents
    Neuropsychopharmacology (2003) 28, 1–13 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents ,1 2,3 2 2 2,3,4 Christine E Marx* , Margaret J VanDoren , Gary E Duncan , Jeffrey A Lieberman and A Leslie Morrow 1Department of Psychiatry and Behavioral Sciences, Duke University Medical Center and Durham VA Medical Center, Durham, North Carolina, USA; 2Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 3Center for Alcohol Studies, University of 4 North Carolina, Chapel Hill, North Carolina 27599, USA; Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599, USA The neuroactive steroid allopregnanolone is a potent g-aminobutyric acid type A (GABAA) receptor modulator with anxiolytic and anticonvulsant effects. Olanzapine and clozapine also have anxiolytic-like effects in behavioral models. We therefore postulated that olanzapine and clozapine would elevate allopregnanolone levels, but risperidone and haloperidol would have minimal effects. Male rats received intraperitoneal olanzapine (2.5–10.0 mg/kg), clozapine (5.0–20.0 mg/kg), risperidone (0.1–1.0 mg/kg), haloperidol (0.1–1.0 mg/ kg), or vehicle. Cerebral cortical allopregnanolone and peripheral progesterone and corticosterone levels were determined. Adrenalectomized animals were also examined. Both olanzapine and clozapine increased cerebral cortical allopregnanolone levels, but neither risperidone nor haloperidol had significant effects. Olanzapine and clozapine also increased serum progesterone and corticosterone levels. Adrenalectomy prevented olanzapine- and clozapine-induced elevations in allopregnanolone. Allopregnanolone induction may contribute to olanzapine and clozapine anxiolytic, antidepressant, and mood-stabilizing actions.
    [Show full text]
  • List Item Olanzapine Teva
    EMA/685358/2012 EMEA/H/C/000810 EPAR summary for the public Olanzapine Teva olanzapine This is a summary of the European public assessment report (EPAR) for Olanzapine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Teva. What is Olanzapine Teva? Olanzapine Teva is a medicine containing the active substance olanzapine. It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as ‘orodispersible’ tablets (5, 10, 15 and 20 mg). Orodispersible tablets are tablets that dissolve in the mouth. Olanzapine Teva is a ‘generic medicine’. This means that Olanzapine Teva is similar to ‘reference medicines’ already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab. For more information on generic medicines, see the question-and-answer document here. What is Olanzapine Teva used for? Olanzapine Teva is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Olanzapine Teva is also effective in maintaining improvement in patients who have responded to an initial course of treatment. Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.
    [Show full text]
  • ARISTADA INITIO® Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ___________________ CONTRAINDICATIONS ___________________ ARISTADA INITIO® safely and effectively. See full prescribing Known hypersensitivity to aripiprazole (4). information for ARISTADA INITIO®. _______________ WARNINGS AND PRECAUTIONS _______________ ARISTADA INITIO® (aripiprazole lauroxil) extended-release injectable • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- suspension, for intramuscular use Related Psychosis: Increased incidence of cerebrovascular adverse Initial U.S. Approval: 2015 reactions (e.g., stroke, transient ischemia attack, including fatalities) (5.2). • Potential for Dosing and Medication Errors: Substitution and dispensing WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS errors between ARISTADA INITIO and ARISTADA could occur. Do not WITH DEMENTIA-RELATED PSYCHOSIS substitute ARISTADA INITIO for ARISTADA (5.3). See full prescribing information for complete boxed warning. • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5.4). • Elderly patients with dementia-related psychosis treated with • Tardive Dyskinesia: Discontinue if clinically appropriate (5.5). antipsychotic drugs are at an increased risk of death. (5.1) • Metabolic Changes: Monitor for hyperglycemia, dyslipidemia, and weight • ARISTADA INITIO is not approved for the treatment of patients with gain (5.6). dementia-related psychosis. (5.1) • Pathological Gambling and Other Compulsive Behaviors:
    [Show full text]
  • Currently Prescribed Psychotropic Medications
    CURRENTLY PRESCRIBED PSYCHOTROPIC MEDICATIONS Schizophrenia Depression Anxiety Disorders 1st generation antipsychotics: Tricyclics: Atarax (hydroxyzine) Haldol (haloperidol), *Anafranil (clomipramine) Ativan (lorazepam) Haldol Decanoate Asendin (amoxapine) BuSpar (buspirone) Loxitane (loxapine) Elavil (amitriptyline) *Inderal (propranolol) Mellaril (thioridazine) Norpramin (desipramine) Keppra (levetiracetam) Navane (thiothixene) Pamelor (nortriptyline) *Klonopin (clonazepam) Prolixin (fluphenazine), Prolixin Sinequan (doxepin) Librium (chlordiazepoxide) Decanoate Spravato (esketamine) Serax (oxazepam) Stelazine (trifluoperazine) Surmontil (trimipramine) Thorazine (chlorpromazine) *Tenormin (atenolol) Tofranil (imipramine) MEDICATIONS PSYCHOTROPIC PRESCRIBED CURRENTLY Trilafon (perphenazine) Tranxene (clorazepate) Vivactil (protriptyline) Valium (diazepam) 2nd generation antipsychotics: Zulresso (brexanolone) Vistaril (hydroxyzine) Abilify (aripiprazole) Aristada (aripiprazole) SSRIs: Xanax (alprazolam) Caplyta (lumateperone) Celexa (citalopram) *Antidepressants, especially SSRIs, are also used in the treatment of anxiety. Clozaril (clozapine) Lexapro (escitalopram) Fanapt (iloperidone) *Luvox (fluvoxamine) Geodon (ziprasidone) Paxil (paroxetine) Stimulants (used in the treatment of ADD/ADHD) Invega (paliperidone) Prozac (fluoxetine) Invega Sustenna Zoloft (sertraline) Adderall (amphetamine and Perseris (Risperidone injectable) dextroamphetamine) Latuda (lurasidone) MAOIs: Azstarys(dexmethylphenidate Rexulti (brexpiprazole) Emsam (selegiline)
    [Show full text]
  • Augmentation of Olanzapine by Fluphenazine Decanoate in Poorly Responsive Schizophrenia Saeed Shoja Shafti 1
    Original Contributions Augmentation of Olanzapine by Fluphenazine Decanoate in Poorly Responsive Schizophrenia Saeed Shoja Shafti 1 Abstract Introduction: Evidence suggests that atypical antipsychotics affect a broader range of schizophrenic psychopathology and are generally better tolerated than conventional antipsychotics. Therefore, they have become the most commonly used class of antipsychotic drugs in clinical practice. But poor compliance and resistance is noteworthy even among those receiving atypical drugs. The objective of this study was to examine whether there could be any encouraging outcome if fluphenazine decanoate was added, as an adjuvant, to olanzapine in poorly responsive cases of schizophre- nia. Method: Twenty-eight female inpatients with a diagnosis of schizophrenia, according to the Structured Clinical Interview for DSM Disorders’ diagnostic criteria, who had shown poor response to olanzapine, were entered into a twelve-week, parallel group, double-blind study for random assignment to either fluphenazine decanoate or placebo in a 1:1 ratio. Primary outcome measures of the study were changes in the mean total scores of the Scale for Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative Symptoms (SANS). The secondary measures were the Schedule for Assessment of Insight (SAI), the Clinical Global Impressions-Severity of Illness (CGI-S) and the Simpson-Angus Scale (SAS). Treatment efficacy was analyzed by t-test, split-plot (mixed) and repeated measures analysis of variance (ANOVA) comparing both groups over twelve weeks. All secondary measures (SAS, SAI, and CGI- S) were analyzed by t-test. Results: According to the findings, the mean total scores of SAPS (P<0.01), SAI (P<0.0001) and CGI-S (P<0.03) in the “fluphenazine plus olanzapine” group were decreased significantly in comparison with the “placebo plus olanzapine group.” In spite of an increase in mean total score of SANS in the target group, there was no significant difference in this regard at the study’s conclusion (P<0.09).
    [Show full text]
  • Antidepressant Medication Management HEDIS Tip Sheet
    HEDIS® Tip Sheet Antidepressant Medication Management Learn how to improve Healthcare Effectiveness Data and Information Set (HEDIS®) rates. This tip sheet gives key details about the Antidepressant Medication Management (AMM) HEDIS measure and best practices. Major depression is one of the most common mental health conditions in the United States, and can result in suicide, the 10th leading cause of death each year.1,2 Although antidepressant medications are an effective treatment to help patients manage their condition, early discontinuation of antidepressants is common – approximately 30% of patients discontinue antidepressants within one month.3 Patients ages 18 and older who were newly treated with an antidepressant medication, had a diagnosis of major depression, and remained on an antidepressant medication treatment. Two rates are reported:4 Rate 1 The percentage of patients who remained on an antidepressant Measure Effective acute medication for at least 84 days phase treatment (12 weeks) Rate 2 The percentage of patients who Effective remained on an antidepressant continuation medication for at least 180 days phase treatment (6 months) • Patients who did not have an encounter with a diagnosis of major depression during a 121-day period: from 60 days Exclusions prior to the Index Prescription Start Date (IPSD), through the IPSD, and 60 days after the IPSD. • Patients who filled a prescription for an antidepressant medication 105 days before the IPSD. (continued) PROVIDER COMMUNICATIONS PROVIDER Coverage for every stage of life™
    [Show full text]
  • Olanzapine Compared to Quetiapine in Adolescents with a First Psychotic
    Olanzapine compared to quetiapine in adolescents with a first psychotic episode Celso Arango, Olalla Robles, Mara Parellada, David Fraguas, Ana Ruiz-Sancho, Oscar Medina, Arantzazu Zabala, Igor Bombín, Dolores Moreno To cite this version: Celso Arango, Olalla Robles, Mara Parellada, David Fraguas, Ana Ruiz-Sancho, et al.. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child and Adolescent Psychiatry, Springer Verlag (Germany), 2009, 18 (7), pp.418-428. 10.1007/s00787-009-0749-5. hal- 00478102 HAL Id: hal-00478102 https://hal.archives-ouvertes.fr/hal-00478102 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur Child Adolesc Psychiatry (2009) 18:418–428 DOI 10.1007/s00787-009-0749-5 ORIGINAL CONTRIBUTION Celso Arango, MD, PhD Olanzapine compared to quetiapine in Olalla Robles, PhD Mara Parellada, MD, PhD adolescents with a first psychotic episode David Fraguas,MD Ana Ruiz-Sancho,MD Oscar Medina,MD Arantzazu Zabala, PhD Igor Bombı´n, PhD Dolores Moreno, MD, PhD j Abstract Objective To com- greater improvement for olanza- Received: 29 March 2008 Accepted: 9 December 2008 pare the efficacy, safety, and pine.
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]
  • High-Risk Medications in the Elderly
    High-Risk Medications in the Elderly The Centers for Medicare & Medicaid Services (CMS) contracted with the National Committee for Quality Assurance (NCQA) to develop clinical strategies to monitor and evaluate the quality of care provided to Medicare beneficiaries. The NCQA’s Geriatric Measurement Advisory Panel identified several categories of medications that have an increased risk of adverse effects to elderly patients. The enclosed chart identifies several key medication categories that CMS and NCQA are monitoring. In an effort to ensure patients’ safety, many of our clients have established pre-authorization protocols for those prescriptions for high risk medications in patients older than 65 years of age. Since pharmacists have a very important role in patient care, we want you to be part of this safety initiative. We strongly encourage that you contact the prescriber when your elderly patient is requesting a new or refilled prescription of a high-risk medication listed on the below chart. Category High Risk Medications Alternatives Analgesics butalbital/APAP Mild Pain: butalbital/APAP/caffeine (ESGIC, FIORICET) acetaminophen, codeine, short-term NSAIDs butalbital /APAP/caffeine/codeine Moderate/Severe Pain: butalbital/ASA/caffeine (FIORINAL) tramadol (ULTRAM), tramadol/APAP* (ULTRACET), butalbital/ASA/caffeine/codeine morphine sulfate (MS CONTIN), ketorolac (TORADOL) hydrocodone/APAP (VICODIN, etc.), oxycodone indomethacin (INDOCIN) (OXYIR), oxycodone/APAP (PERCOCET), fentanyl meperidina (DEMEROL) patch (DURAGESIC), OXYCONTIN
    [Show full text]